The U.S. Naloxone market comprises pharmaceutical products that are used to reverse opioid overdoses. Naloxone products such as nasal spray and injectable forms are used in emergency situations to counteract life-threatening effects of opioid overdose such as extreme drowsiness, respiratory issues, or loss of consciousness. The ease of self or buddy administration of naloxone nasal sprays has significantly increased their demand in preventing opioid overdose deaths. The global U.S. Naloxone Market is estimated to be valued at US$ 1,390.7 Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising rate of opioid overdose across the U.S. has been a major driver of growth for the naloxone market. According to the Centers for Disease Control and Prevention (CDC), there were over 93,000 drug overdose deaths in the U.S. during 2020, out of which 64,000 were opioid-related. The continuing opioid epidemic and increasing availability of potent synthetic opioids like fentanyl has led to greater demand for naloxone products, which have proven effective in reversing overdoses caused by prescribed and illicit opioids. The introduction of generic and affordable naloxone nasal sprays has enabled broader access to this life-saving medication and further propelled the U.S. naloxone market growth in recent years.
SWOT Analysis
Strength: The U.S. Naloxone market has high demand for opioid overdose treatment drugs. Naloxone effectively reverses opioid overdoses and saves lives.
Weakness: Naloxone has a short half-life and multiple doses may be required to revive a patient in case of an overdose of long-acting opioids. Recurrence of overdose after naloxone wears off can occur.
Opportunity: Increasing initiatives by nonprofit organizations and governments to distribute naloxone kits widely for public use present an opportunity for market growth.
Threats: Alternative treatment options and strict regulations on opioid drugs pose threats to the sustained growth of the U.S. naloxone market.
Key Takeaways
The global U.S. Naloxone market is expected to witness high growth over the forecast period between 2023 to 2030. The market size for 2024 is projected to be US$ 1,390.7 Mn registering a CAGR of 10.% during the forecast period.
Regional analysis: The Northeast region of the U.S. accounts for the major share of the naloxone market currently due to higher prevalence of opioid overdoses. States like New York and New Jersey are among the fastest growing regional markets.
Key players: Key players operating in the U.S. Naloxone market are Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., Kern Pharma, S.L., Samarth Life Sciences Pvt. Ltd., Opiant Pharmaceuticals, Pfizer, Sandoz, and Amneal Pharmaceuticals. These players are focused on developing generic and easy-to-administer naloxone products.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.